Axon Enterprise (NASDAQ:AXON) Raised to “Hold” at Wall Street Zen

Axon Enterprise (NASDAQ:AXON) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities research analysts have also recently commented on AXON. Royal Bank Of Canada lowered their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. The Goldman Sachs Group lowered their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Craig Hallum reaffirmed a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a research report on Wednesday. Finally, TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $542.40 on Friday. The company has a market capitalization of $43.61 billion, a P/E ratio of 356.84, a price-to-earnings-growth ratio of 12.23 and a beta of 1.46. The company’s 50-day moving average is $537.92 and its 200 day moving average is $623.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. Axon Enterprise has a fifty-two week low of $396.41 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the company posted $2.08 earnings per share. On average, equities research analysts forecast that Axon Enterprise will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the transaction, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 1,797 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total transaction of $968,996.31. Following the transaction, the insider directly owned 83,485 shares of the company’s stock, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,040 shares of company stock worth $32,251,738 over the last quarter. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AXON. Vanguard Group Inc. raised its position in shares of Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after buying an additional 53,060 shares in the last quarter. Geode Capital Management LLC increased its stake in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares during the last quarter. Baillie Gifford & Co. raised its holdings in shares of Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after acquiring an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its holdings in shares of Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after acquiring an additional 1,179,038 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.